Literature DB >> 110689

Effect of type-specific active immunization on the development and progression of experimental Pseudomonas aeruginosa endocarditis.

G L Archer, J L Johnston.   

Abstract

Rabbits with intracardiac catheters were immunized with heat-killed Pseudomonas aeruginosa or saline and challenged with either 10(9) (high inoculum) or 10(7) (low inoculum) pseudomonas. Immunization did not decrease the incidence of endocarditis when compared with controls, but it did significantly prolong survival. The longer survival of immunized rabbits after high-inoculum challenge was not due to prolongation of the course of endocarditis but to type-specific protection from early, overwhelming bacteremia. However, after low-inoculum challenge there were no early deaths and there was a significantly (P < 0.01) longer survival of immunized (17.4 days) than unimmunized (10.6 days) animals dying of endocarditis. Increased survival was associated with higher total and 2-mercaptoethanol-resistant hemagglutinating antibody titers 1 week after challenge in immunized as compared with unimmunized rabbits. Early (48 h after challenge) vegetation colonization was also significantly (P < 0.05) greater after type-specific as opposed to non-type-specific or saline immunization and low-inoculum challenge. However, whereas 67% of type-specifically immunized rabbits had colonized vegetations at 48 h, only 38.9% died with bacteremic endocarditis. Another 19.2% of immunized rabbits had vegetations colonized with > 10(5) colony-forming units of pseudomonas at elective sacrifice 2 weeks after challenge but no bacteremia; no unimmunized rabbit exhibited similar late colonization. Preexisting antibody may be important in the pathogenesis of pseudomonas endocarditis in drug addicts, and its presence may explain the subacute and often protracted course of the disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 110689      PMCID: PMC414279          DOI: 10.1128/iai.24.1.167-173.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  11 in total

1.  USE OF VACCINE AND HYPERIMMUNE SERUM FOR PROTECTION AGAINST PSEUDOMONAS SEPTICEMIA.

Authors:  I FELLER; A B VIAL; W CALLAHAN; J WALDYKE
Journal:  J Trauma       Date:  1964-07

2.  Bacterial endocarditis; an experimental study of healing.

Authors:  M G McGEOWN
Journal:  J Pathol Bacteriol       Date:  1954-01

Review 3.  Pathoanatomic, pathophysiologic and clinical correlations in endocarditis (first of two parts).

Authors:  L Weinstein; J J Schlesinger
Journal:  N Engl J Med       Date:  1974-10-17       Impact factor: 91.245

4.  Pseudomonas aeruginosa endocarditis in drug addicts.

Authors:  G Archer; F R Fekety; R Supena
Journal:  Am Heart J       Date:  1974-11       Impact factor: 4.749

5.  Heat-stable opsonins in sera of patients with Pseudomonas infections.

Authors:  J G Crowder; H B Devlin; M Fisher; A White
Journal:  J Lab Clin Med       Date:  1974-06

6.  Pseudomonas endocarditis: hemagglutinating antibodies to Fisher-Devlin-Gnabasik immunotypes in sera.

Authors:  M P Reyes; M W Fisher; A M Lerner
Journal:  J Lab Clin Med       Date:  1974-06

7.  Type-specific immunity in pseudomonas diseases.

Authors:  J G Crowder; M W Fisher; A White
Journal:  J Lab Clin Med       Date:  1972-01

8.  Experimental endocarditis due to Pseudomonas aeruginosa. I. Description of a model.

Authors:  G Archer; F R Fekety
Journal:  J Infect Dis       Date:  1976-07       Impact factor: 5.226

9.  Passive immunity against pseudomonas sepsis during granulocytopenia.

Authors:  L Harvath; B R Andersen; H J Amirault
Journal:  Infect Immun       Date:  1976-11       Impact factor: 3.441

10.  Evaluation of type-specific and non-type-specific pseudomonas vaccine for treatment of pseudomonas sepsis during granulocytopenia.

Authors:  L Harvath; B R Andersen
Journal:  Infect Immun       Date:  1976-04       Impact factor: 3.441

View more
  10 in total

1.  Immunization with FimA protects against Streptococcus parasanguis endocarditis in rats.

Authors:  H B Viscount; C L Munro; D Burnette-Curley; D L Peterson; F L Macrina
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

2.  Influence of preformed antibody on the pathogenesis of experimental Candida albicans endocarditis.

Authors:  W M Scheld; R A Calderone; J P Brodeur; M A Sande
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

3.  Antibodies to a surface-exposed, N-terminal domain of aggregation substance are not protective in the rabbit model of Enterococcus faecalis infective endocarditis.

Authors:  J K McCormick; H Hirt; C M Waters; T J Tripp; G M Dunny; P M Schlievert
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Role of culture conditions and immunization in experimental nutritionally variant streptococcal endocarditis.

Authors:  I van de Rijn
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

5.  Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits.

Authors:  D P Greenberg; J I Ward; A S Bayer
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

6.  Role of granulocytes and monocytes in experimental Escherichia coli endocarditis.

Authors:  M J Meddens; J Thompson; W C Bauer; R van Furth
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

7.  Effect of immunization on the genesis of pneumococcal endocarditis in rabbits.

Authors:  S W Adler; D S Selinger; W P Reed
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

8.  Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis.

Authors:  J Nemeth; J C Lee
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

9.  Effects of immunization and anticoagulation on the development of experimental Escherichia coli endocarditis.

Authors:  L Thörig; J Thompson; R van Furth
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

10.  Enhancement of experimental bacteremia and endocarditis caused by dysgonic fermenter (DF-2) bacterium after treatment with methylprednisolone and after splenectomy.

Authors:  T Butler; K H Johnston; Y Gutierrez; M Aikawa; R Cardaman
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.